Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase in late-window acute ischemic stroke
NCT03785678Phase 3Completed
- Sponsor
- Genentech
- Start
- Mar 2019
- Primary completion
- Feb 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Tenecteplase with Placebo (2 arms). Primary endpoint: Modified Rankin Scale Score at 90 days. Started Mar 2019; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03785678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785678.